



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

Date: April 02, 2024

To,
The Manager
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Ref: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Incorporation of Limited Liability Partnership.

Dear Sir/Madam,

As per the subject captioned above and pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, as amended, we hereby inform you that the Company along with two other Designated Partners has incorporated a Limited Liability Partnership namely "Aspira DNA Diagnostics Gujarat LLP" today under LLPIN: ACG-3843.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 09, 2015 is attached herewith as "Annexure A".

You are requested to kindly take above information on your record.

Thanking you,

Yours Faithfully,

For **Aspira Pathlab & Diagnostics Limited**



Nikunj Mange
Executive Director

Encl: As above



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

Annexure-A

a)	Name of the target entity, details in brief such as size, turnover etc.;	Name: Aspira DNA Diagnostics Gujarat LLP LLPIN: ACG-3843 Contribution: Rs 26,00,000/- (Rupees Twenty Six Lakhs Only) Turnover: Nil (Yet to commence business operations)
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	Not applicable
c)	Industry to which the entity being acquired belongs	Healthcare Services
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To undertake pathological testing and provide other diagnostics and healthcare services.
e)	brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
f)	Indicative time period for completion of the acquisition	Not applicable
g)	nature of consideration -whether cash consideration or share swap and details of the same	Cash Consideration
h)	cost of acquisition or the price at which the shares are acquired	75 Lakhs
i)	percentage of shareholding / control acquired and / or number of shares acquired	50%
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Aspira DNA Diagnostics Gujarat LLP is incorporated under the Limited Liability Partnership Act , 2008 and registered with Registrar of Companies, Mumbai (Maharashtra) on April 02,2024 and is yet to commence its business operations.